For how we live.
A cohort of 5.24 million UK adults linked higher BMI to 17 of 22 cancers — strongly for the uterus, weakly or not at all for others, and inversely for a couple. The pattern is specific, not uniform.
A small single-arm trial of the PD-1/CTLA-4 antibody cadonilimab with lenvatinib reported a 40.6% response rate in previously treated advanced endometrial cancer.
Six products got revised labels in February 2026, removing cardiovascular, breast cancer, and dementia language. The scientific societies that welcomed the change also listed the distinctions the new label does not make.
In 53,100 California women, higher trihalomethanes in drinking water tracked with modestly higher uterine cancer risk. Nitrate, arsenic and uranium showed no link.
Women whose habits aligned with a favorable estrogen-metabolism pathway had up to 61% lower endometrial cancer risk. The score explains only a tenth of the variation it predicts.
A Taiwanese cohort of 26,000 women aged 20 to 50 puts numbers on a known tamoxifen risk in a population — younger, premenopausal — where data has been thinner.
A 444,000-patient records study found a two-thirds lower rate of endometrial cancer when GLP-1 receptor agonists were added to progestin therapy. The two groups differed by eight years in average age.